Clinical Trial Update: MED Study to Evaluate the Safety, Tolerability and Pharmacokinetics of Intravenous WCK 5222 (Zidebactam and Cefepime) in Healthy Volunteers [Phase 1]

View source ↗

Summary

Phase 1 study of the WCK 5222 combination (Zidebactam and Cefepime) in healthy volunteers to evaluate safety, tolerability, and pharmacokinetics has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Gram-negative Bacterial Infections

Drugs mentioned

• WCK 5222 (Zidebactam and Cefepime)

Snippet

Sponsor: Wockhardt | Conditions: Serious Gram-negative Infections | Phase 1 | Status: COMPLETED